In metastatic colorectal cancer (mCRC), the ORR to BRAFi and BRAFi/MEKi combinations is much lower, <15% in some trials (1), and well-characterized BRAFi resistance mechanisms in mCRC include bypass signaling via epidermal growth factor receptor (EGFR) (1). The gene discussed is EGFR; the disease is metastatic colorectal cancer.